The mechanisms of action of metformin
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Metformin is a widely-used drug that results in clear benefits in relation to glucose metabolism and diabetes-related complications. The mechanisms underlying these benefits are complex and still not fully understood. Physiologically, metformin has been shown to reduce hepatic glucose production, yet not all of its effects can be explained by this mechanism and there is increasing evidence of a key role for the gut. At the molecular level the findings vary depending on the doses of metformin used and duration of treatment, with clear differences between acute and chronic administration. Metformin has been shown to act via both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms; by inhibition of mitochondrial respiration but also perhaps by inhibition of mitochondrial glycerophosphate dehydrogenase, and a mechanism involving the lysosome. In the last 10 years, we have moved from a simple picture, that metformin improves glycaemia by acting on the liver via AMPK activation, to a much more complex picture reflecting its multiple modes of action. More work is required to truly understand how this drug works in its target population: individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 The multiple mechanism via which metformin affects liver metabolism. Note that the possible effect of metformin on mitochondrial glycerophosphate dehydrogenase [7] has not been included. (1) Uptake of metformin into hepatocytes is catalysed by the organic cation transporter-1 (OCT1) [11]. Being positively charged, the drug accumulates in cells and, further, in the mitochondria because of the membrane potentials across the plasma membrane and the mitochondrial inner membrane [14]. (2) Metformin inhibits Complex I, preventing mitochondrial ATP production and, thus, increasing cytoplasmic ADP:ATP and AMP:ATP ratios (the latter by displacement of the adenylate kinase reaction); these changes activate AMPK [17]. (3) Alternatively, AMPK may be activated by a lysosomal mechanism, not shown in detail here but requiring Axin and late endosomal/lysosomal adaptor, MAPK and mTOR activator 1 (LAMTOR1) [27]. (4) Increases in AMP:ATP ratio also inhibit fructose-1,6-bisphosphatase (FBPase), resulting in the acute inhibition of gluconeogenesis [30], while also inhibiting adenylate cyclase and lowering cAMP production [32]. (5) Activated AMPK phosphorylates the ACC1 and ACC2 isoforms of ACC, inhibiting fat synthesis and promoting fat oxidation instead, thus reducing hepatic lipid stores and enhancing hepatic insulin sensitivity [34]. (6) AMPK also phosphorylates and activates the cAMP-specific 3′,5′-cyclic phosphodiesterase 4B (PDE4B), thus lowering cAMP by another mechanism [33]. (7) Glucagon-induced increases in cAMP activate cAMP-dependent protein kinase A (PKA), causing a switch from glycolysis to gluconeogenesis via phosphorylation and inactivation of PFKFB1, causing a decrease in fructose-2,6-bisphosphate (F2,6BP), an allosteric activator of phosphofructokinase (PFK) and inhibitor of fructose-1,6-bisphosphatase (FBPase). (8) PKA also phosphorylates and inactivates the liver isoform of the glycolytic enzyme pyruvate kinase (Pyr K) and (9) phosphorylates the transcription factor cAMP response element binding protein (CREB), thus inducing transcription of the genes encoding the gluconeogenic enzymes PEPCK and G6Pase. (10) Phosphorylation of CREB-regulated transcriptional co-activator-2 (CRTC2) by AMPK, or by AMPK-related kinases such as salt-inducible kinase 2 (SIK2), causes CRTC2 to be retained in the cytoplasm, antagonising the effects of PKA on the transcription of PEPCK and G6Pase [61, 62]. PKA inhibits SIK2 by direct phosphorylation at multiple sites [62]. Ac-CoA, acetyl-CoA; BPG, 1,3-bisphosphoglycerate; DHAP, dihydroxyacetone phosphate; FBP, fructose 1,6-bisphosphate; F6P, fructose 6-phosphate; G3P, glyceraldehyde 3-phosphate; G6P, glucose 6-phosphate; Ma-CoA, malonyl-CoA; OAA, oxaloacetate; PEP, phosphoenolpyruvate; 3PG, 3-phosphoglycerate](https://figures.cochat.ai/paper-figures/0564c378c93b4ad9a7f3bef182b8953c/the-mechanisms-of-action-of-metformin-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Metformin primarily reduces hepatic glucose production, while GLP-1RAs enhance insulin secretion in response to meals20–22.”
From Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a mechanistic perspective, metformin is known to increase insulin sensitivity by inhibiting the production of hepatic glucose, as well as inhibiting gluconeogenesis and lipogenesis, resulting in a decrease in circulating insulin and glucose.54”
From The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“Since it causes a switch from synthesis of cellular nutrient stores to their breakdown, the idea that AMPK might be involved in metformin action was attractive and, in 2001, metformin was reported to activate AMPK in rat hepatocytes and rat liver in vivo [26].”
BackgroundAMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Self-citationWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 3×
“The most intensively studied mitochondrial action of metformin is the inhibition of Complex I of the respiratory chain [14, 16], which suppresses ATP production.”
BackgroundDisentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
Shin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 2×
“The most intensively studied mitochondrial action of metformin is the inhibition of Complex I of the respiratory chain [14, 16], which suppresses ATP production.”
BackgroundClinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 1×
“small intestine with the remainder passing into the colon before being excreted in faeces [4].”
BackgroundMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 3×
“Note that the possible effect of metformin on mitochondrial glycerophosphate dehydrogenase [7] has not been included.”
BackgroundInfluentialCorton, J. M., Gillespie, J. G., Hawley, S. A., & Hardie, D. G. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.0558k.x · Cited by 1,230
Self-citationForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 3×
“Since ACC phosphorylation is abolished by AMPK knockout [31], the long-term insulin-sensitising effects of metformin appear to be mediated entirely by AMPK.”
BackgroundInfluentialKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 1×
“Metformin intolerance Metformin treatment is frequently associated with GI side effects (20–30% of patients) [45] with severe side effects resulting in metformin discontinuation in ~5% of patients.”
BackgroundThe CREB coactivator TORC2 is a key regulator of fasting glucose metabolism
Koo, S.-H., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P., et al. (2005) · Nature · doi:10.1038/nature03967 · Cited by 995
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 967
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H. M., Noori, T., Weinkove, D., Schuster, E., Greene, N. D. E., & Gems, D. (2013) · Cell · doi:10.1016/j.cell.2013.02.035 · Cited by 967 · cited 1×
“In the nematode worm, Caenorhabditis elegans, metformin lengthens lifespan through effects on intestinal microbial growth [49].”
BackgroundFullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
Self-citationBiguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833
Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation
Hawley, S. A., Ross, F. A., Chevtzoff, C., Green, K. A., Evans, A., Fogarty, S., Towler, M. C., Brown, L. J., Ogunbayo, O. A., Evans, A. M., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.001 · Cited by 773 · cited 2×
“(2)Metformin inhibits Complex I, preventingmitochondrial ATP production and, thus, increasing cytoplasmic ADP:ATP and AMP:ATP ratios (the latter by displacement of the adenylate kinase reaction); these changes activate AMPK [17].”
Self-citationMetformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733 · cited 1×
“There are a number of putative mechanisms for how metformin could impact on glucose metabolism via actions on the intestines (reviewed in [40]).”
BackgroundSelf-citationAnti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704 · cited 2×
“In addition, metformin suppresses several inflammatory cytokines in human plasma in individuals without diabetes [53].”
BackgroundSelf-citationEffects of metformin and other biguanides on oxidative phosphorylation in mitochondria
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014) · Biochemical Journal · doi:10.1042/bj20140620 · Cited by 661 · cited 1×
“A persistent criticism of this mechanism has been the high extracellular concentrations (mmol/l) required to observe rapid effects, although lower concentrations of metformin (50–100 μmol/l) do inhibit Complex I in rat hepatoma (H4IIE) cells after several hours; this delay was ascribed to the slow uptake ofmetformin b…”
BackgroundInvolvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441 · cited 7×
“For example, the studies we report on the role of OCT1 inmetformin intolerance would support an approach whereby OCT1-interacting drugs (such as proton pump inhibitors) are avoided in individuals experiencing GI side effects with metformin use [47].”
BackgroundInfluentialCommon variants near ATM are associated with glycemic response to metformin in type 2 diabetes
The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, & The Wellcome Trust Case Control Consortium 2 (2011) · Nature Genetics · doi:10.1038/ng.735 · Cited by 432
Howell, J. J., Hellberg, K., Turner, M., Talbott, G., Kolar, M. J., Ross, D. S., Hoxhaj, G., Saghatelian, A., Shaw, R. J., & Manning, B. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.009 · Cited by 408 · cited 1×
“elegans [56, 57], with AMPK-dependent and -independent mechanisms identified [57].”
BackgroundMetformin Activates a Duodenal Ampk-Dependent Pathway to Lower Hepatic Glucose Production in Rats
Duca, F. A., Côté, C. D., Rasmussen, B. A., Zadeh-Tahmasebi, M., Rutter, G. A., Filippi, B. M., & Lam, T. K. T. (2015) · Nature Medicine · doi:10.1038/nm.3787 · Cited by 402
Griffin, S. J., Leaver, J. K., & Irving, G. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4337-9 · Cited by 398
Vasamsetti, S. B., Karnewar, S., Kanugula, A. K., Thatipalli, A. R., Kumar, J. M., & Kotamraju, S. (2015) · Diabetes · doi:10.2337/db14-1225 · Cited by 397 · cited 1×
“Metformin has, for example, been shown to have direct effects on inflammation, including effects on NF-κB signalling and differentiation of monocytes into macrophages [52, 53], as well as suppressing proinflammatory cytokines from these macrophages.”
BackgroundLochhead, P. A., Salt, I. P., Walker, K. S., Hardie, D. G., & Sutherland, C. (2000) · Diabetes · doi:10.2337/diabetes.49.6.896 · Cited by 390
Self-citationAMP ‐activated protein kinase: a cellular energy sensor that comes in 12 flavours
Ross, F. A., MacKintosh, C., & Hardie, D. G. (2016) · The FEBS Journal · doi:10.1111/febs.13698 · Cited by 381
Self-citationNatali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
Bannister, C. A., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12354 · Cited by 356 · cited 1×
“It is possible that recent observations, consistent with the ability of metformin to prolong mammalian lifespan [54, 55], may, at”
BackgroundBuse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325 · cited 1×
“Third, a delayedrelease metformin that is largely retained in the gut, with minimal systemic absorption, is as effective at lowering blood glucose as the standard immediate-release formulation in individuals with type 2 diabetes [39].”
BackgroundRepurposing metformin for the prevention of cancer and cancer recurrence
Heckman-Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V., & Ford, L. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4372-6 · Cited by 297
Metformin activates AMPK through the lysosomal pathway
Zhang, C.-S., Li, M., Ma, T., Zong, Y., Cui, J., Feng, J.-W., Wu, Y.-Q., Lin, S.-Y., & Lin, S.-C. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.003 · Cited by 280 · cited 3×
“2), the latter being a lysosomal protein [27].”
BackgroundInfluentialDujic, T., Zhou, K., Donnelly, L. A., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2015) · Diabetes · doi:10.2337/db14-1388 · Cited by 278
Self-citationBailey, C. J., Wilcock, C., & Scarpello, J. H. B. (2008) · Diabetologia · doi:10.1007/s00125-008-1053-5 · Cited by 275
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
MetGen Investigators, Zhou, K., DPP Investigators, ACCORD Investigators, Yee, S. W., Seiser, E. L., van Leeuwen, N., Tavendale, R., Bennett, A. J., Groves, C. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3632 · Cited by 234
Self-citationAn Ancient, Unified Mechanism for Metformin Growth Inhibition in C. Elegans and Cancer
Wu, L., Zhou, B., Oshiro-Rapley, N., Li, M., Paulo, J. A., Webster, C. M., Mou, F., Kacergis, M. C., Talkowski, M. E., Carr, C. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.055 · Cited by 227
Inhibition by AICA Riboside of Gluconeogenesis in Isolated Rat Hepatocytes
Vincent, M. F., Marangos, P. J., Gruber, H. E., & van den Berghe, G. (1991) · Diabetes · doi:10.2337/diab.40.10.1259 · Cited by 217
Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S. F., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N. A., et al. (2009) · Diabetes · doi:10.2337/db08-0896 · Cited by 184
Self-citationThe LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver
Patel, K., Foretz, M., Marion, A., Campbell, D. G., Gourlay, R., Boudaba, N., Tournier, E., Titchenell, P., Peggie, M., Deak, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5535 · Cited by 161
Importance of the intestine as a site of metformin‐stimulated glucose utilization
Bailey, C. J., Mynett, K. J., & Page, T. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb13128.x · Cited by 147
Johanns, M., Lai, Y.-C., Hsu, M.-F., Jacobs, R., Vertommen, D., Van Sande, J., Dumont, J. E., Woods, A., Carling, D., Hue, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms10856 · Cited by 144
Gormsen, L. C., Sundelin, E. I., Jensen, J. B., Vendelbo, M. H., Jakobsen, S., Munk, O. L., Hougaard Christensen, M. M., Brøsen, K., Frøkiær, J., & Jessen, N. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177774 · Cited by 143
Metformin and ageing: improving ageing outcomes beyond glycaemic control
Valencia, W. M., Palacio, A., Tamariz, L., & Florez, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4349-5 · Cited by 142
DeFronzo, R. A., Buse, J. B., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetologia · doi:10.1007/s00125-016-3992-6 · Cited by 128
Cellular Responses to the Metal-Binding Properties of Metformin
Logie, L., Harthill, J., Patel, K., Bacon, S., Hamilton, D. L., Macrae, K., McDougall, G., Wang, H.-H., Xue, L., Jiang, H., et al. (2012) · Diabetes · doi:10.2337/db11-0961 · Cited by 108
Self-citationVariants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta‐Analysis
Dujic, T., Zhou, K., Yee, S., van Leeuwen, N., de Keyser, C., Javorský, M., Goswami, S., Zaharenko, L., Hougaard Christensen, M., Out, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.567 · Cited by 108
Self-citationSundelin, E., Gormsen, L., Jensen, J., Vendelbo, M., Jakobsen, S., Munk, O., Christensen, M., Brøsen, K., Frøkiær, J., & Jessen, N. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.701 · Cited by 100
The pharmacogenetics of metformin
Florez, J. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4335-y · Cited by 90
Buse, J. B., Rodbard, H. W., Trescoli Serrano, C., Luo, J., Ivanyi, T., Bue-Valleskey, J., Hartman, M. L., Carey, M. A., & Chang, A. M. (2016) · Diabetes Care · doi:10.2337/dc15-1531 · Cited by 82
Control of Gluconeogenesis by Metformin: Does Redox Trump Energy Charge?
Baur, J. A., & Birnbaum, M. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.013 · Cited by 73
Schäfer, G. (1976) · Biochemical Pharmacology · doi:10.1016/0006-2952(76)90423-8 · Cited by 71
Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors
Cubeddu, L. X., Bönisch, H., Göthert, M., Molderings, G. J., Racké, K., Ramadori, G. P., Miller, K. J., & Schwörer, H. (2000) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900152 · Cited by 67
Massollo, M., Marini, C., Brignone, M., Emionite, L., Salani, B., Riondato, M., Capitanio, S., Fiz, F., Democrito, A., Amaro, A., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.106666 · Cited by 59
Preiss, D., Dawed, A., Welsh, P., Heggie, A., Jones, A. G., Dekker, J., Koivula, R., Hansen, T. H., Stewart, C., Holman, R. R., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12826 · Cited by 59
Self-citationPryor, H. J., Smyth, J. E., Quinlan, P. T., & Halestrap, A. P. (1987) · Biochemical Journal · doi:10.1042/bj2470449 · Cited by 56
Dujic, T., Zhou, K., Tavendale, R., Palmer, C. N. A., & Pearson, E. R. (2016) · Diabetes Care · doi:10.2337/dc16-0706 · Cited by 56
Self-citationBiomolecular Mode of Action of Metformin in Relation to Its Copper Binding Properties
Repiščák, P., Erhardt, S., Rena, G., & Paterson, M. J. (2014) · Biochemistry · doi:10.1021/bi401444n · Cited by 52
Self-citationZur Pharmakologie des Galegins
Müller, H., & Reinwein, H. (1927) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf01862957 · Cited by 41
The copper binding properties of metformin – QCM-D, XPS and nanobead agglomeration
Quan, X., Uddin, R., Heiskanen, A. R., Parmvi, M., Nilson, K., Donolato, M., Hansen, M. F., Rena, G., & Boisen, A. (2015) · Chemical Communications · doi:10.1039/c5cc04321b · Cited by 27
Self-citationAgrawal, S., & Gupta, Y. (2016) · Diabetes Care · doi:10.2337/dc16-1340 · Cited by 25
Research works printed but not linked: 2
- Howlett HCS, Bailey CJ (2007) Galegine and antidiabetic plants. In: Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P (eds) Metformin—the gold standard. Wiley, Chichester, pp 3–9
- Howlett HCS, Bailey CJ (2007) Discovery of metformin. In: Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P (eds) Metformin—the gold standard. Wiley, Chichester, pp 11–16
Cited by
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.005 · Cited by 1,787
“Among the many proposed mechanisms of action of metformin is activation of AMPK: This is now thought to be a secondary effect of inhibition of the mitochondrial respiratory chain.(96) Such effects of metformin may act directly (ie, independent of blood glucose lowering) on other tissues, including vascular endothelial…”
BackgroundChait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Zatterale, F., Longo, M., Naderi, J., Raciti, G. A., Desiderio, A., Miele, C., & Beguinot, F. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01607 · Cited by 1,180
Insulin Resistance: From Mechanisms to Therapeutic Strategies
Lee, S.-H., Park, S.-Y., & Choi, C. S. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0280 · Cited by 1,092
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003
Metadata
- Authors
- Rena, G., Hardie, D. G., & Pearson, E. R.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Hardie, D. Grahame
- Pearson, Ewan R.
- Venue
- Diabetologia
- Published
- 2017-08-03
- Volume
- 60
- Issue
- 9
- Pages
- 1577-1585
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC5552828
- OpenAlex
- W2743010525
- Cited by
- 2,287
- References
- 64
- Citations by year
- 2026: 227 · 2025: 264 · 2024: 271 · 2023: 288 · 2022: 326 · 2021: 312 · 2020: 302 · 2019: 158 · 2018: 120 · 2017: 13
- FWCI
- 15.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, cc-by)
- Funders
- University of Dundee
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, mechanism of action, type 2 diabetes, glucose metabolism, hepatic glucose production, AMPK, AMPK-independent mechanism, mitochondrial respiration, lysosomes, intestine, dose-dependent effects
- MeSH terms
- Animals, Biguanides, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.